Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
SPTX: Glyph platform enables novel oral therapies for depression and anxiety, advancing toward pivotal trials
3+ day, 14+ hour ago (82+ words) TradingView SPTX: Glyph platform enables novel oral therapies for depression and anxiety, advancing toward pivotal trials The company presented its neuroscience-focused pipeline, highlighting the Glyph platform's ability to overcome oral bioavailability and liver toxicity issues. Lead programs GlyphAllo and GlyphAgo…...
Blocking cellular stress protein may help ease Rett symptoms
1+ week, 3+ day ago (618+ words) Mouse study suggests targeting HSF1 pathway eases motor problems Written by Steve Bryson, PhD | Sept. 2, 2026 Blocking HSF1, a protein active during the cellular stress response, may be a novel therapeutic target for easing symptoms in Rett syndrome, a new study suggests. Researchers…...
Social anxiety drugs have been floundering in the clinic. Could Eli Lilly help tip the scales?
1+ week, 5+ day ago (840+ words) After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year. Drug developers have successfully tackled general anxiety with a number of innovations. But social anxiety disorder, which…...
Entropy takes TRP-8803 to the US in head-to-head depression trial - BioPharmaDispatch
2+ week, 4+ day ago (143+ words) Entropy takes TRP-8803 to the US in head-to-head depression trial PharmaDispatch Entropy takes TRP-8803 to the US in head-to-head depression trial Entropy Neurodynamics has signed an agreement with the University of California, San Francisco, to develop a US Phase 2 trial…...
Beyond Weight Loss: Glucagon-Like Peptide-1 Receptor Agonists and Antipsychotic Adherence in Schizophrenia
3+ week, 1+ day ago (23+ words) Cureus Download Cureus Media Kit Public user content licensed CC-BY 4.0...